GHRS
GH Research PLC
NASDAQ · Healthcare · Biotechnology · IE
$28.23
+1.11%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.27
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.23
- EPS estimate
- -$0.29
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +6.4%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Strong Buy
- Price target
- $41
- PT range
- $39 – $44
- Analysts
- 4
4 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026